Safety outcomes
bleeding
BLEEDING, SECONDARY
The bleeding rate in COVID-PREVENT was overall low. The primary safety outcome occurred in only 1 of 111 patients (0.9%) of the whole study population. The patients randomized to the rivaroxaban group had a non-fatal major bleeding according to the ISTH criteria. The secondary efficacy outcome defined as non-major clinically relevant bleeding occurred in two patients in the rivaroxaban-group and in three patients in the SOC-group (Table Secondary outcomes